secwatch.observer — SEC 8-K summary
======================================

Issuer:     PRECIGEN, INC. (PGEN)
CIK:        0001356090
Form:       8-K
Filed at:   2022-08-08T23:59:59+00:00
Accession:  0000950103-22-013773
Event type: earnings
Sentiment:  neutral
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Precigen Q2 loss from cont. ops $26.1M; divests Trans Ova Genetics for $170M
----------------------------------------------------------------------------

- Loss from continuing ops $26.1M ($0.13 loss per share) vs $30.9M loss in Q2 2021.
- Total revenues down 24% YoY; SG&A decreased 15%.
- Agreed to sell Trans Ova Genetics to URUS for $170M cash upfront plus up to $10M earn-out; close expected Q3 2022.
- Cash and investments $132.8M as of June 30, 2022; proceeds intended to pay convertible notes due July 2023.
- Believes cash plus cost reductions provide runway into Q4 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1356090/000095010322013773/0000950103-22-013773-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1356090/000095010322013773/dp178450_8k.htm
  HTML page:      https://secwatch.observer/filing/0000950103-22-013773

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer